Director George Morrow filed a Form 144 notice with the SEC on October 30, 2026, disclosing a proposed sale of 300 shares of Neurocrine Biosciences, Inc. common stock acquired through a stock option exercise.

Key Highlights

  • Filer: George Morrow, a director of Neurocrine Biosciences, Inc., filed the notice.
  • Shares proposed for sale: 300 shares of common stock, with an aggregate market value of $43,914.00 as stated in the filing.
  • Acquisition method: The 300 shares were acquired on October 30, 2026, through an exercise of stock options granted by the issuer, with cash payment made the same day.
  • Approximate date of sale: October 30, 2026, to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services.
  • 10b5-1 plan: The filing indicates a Rule 10b5-1 plan adoption date of May 26, 2026.
  • Shares outstanding: According to the filing, 101,649,181 shares of common stock were outstanding at the time of notice.
  • Prior 3-month sales: The filing reports nothing to report for securities sold during the past three months.

Neurocrine Biosciences Director Morrow Discloses Proposed Stock Sale Under Rule 144

According to the Form 144 filing, George Morrow, identified as a director of Neurocrine Biosciences, Inc. (NASDAQ:NBIX), proposed to sell 300 shares of the company's common stock. The aggregate market value of those shares was listed as $43,914.00. The proposed sale is to be handled through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004, on approximately October 30, 2026.

The filing discloses that the 300 shares subject to the proposed sale were acquired on October 30, 2026, via an exercise of stock options, with the issuer named as the person from whom the securities were acquired. Payment was made in cash on the same date. The filing further notes that the transaction is being conducted pursuant to a Rule 10b5-1 trading plan adopted on May 26, 2026.

The filing states that no securities of the issuer were sold by Morrow during the three months preceding this notice. At the time of the filing, Neurocrine Biosciences reported 101,649,181 shares of common stock outstanding. By signing the Form 144, Morrow represented, as of the plan adoption date, that he was not aware of any material adverse information regarding the current and prospective operations of Neurocrine Biosciences that had not been publicly disclosed.

What Was Disclosed

Director George Morrow filed a Form 144 notice on October 30, 2026, disclosing a proposed sale of 300 shares of Neurocrine Biosciences common stock, acquired via option exercise, with an aggregate market value of $43,914.00, under a Rule 10b5-1 plan adopted May 26, 2026.